BiotechTube
Home/Eisai/Haruo Naito
HN

Haruo Naito

Former CEO, Architect of hhc Philosophy

Eisai

Therapeutic Areas

NeurologyOncology

Eisai Pipeline

DrugIndicationPhase
Lecanemab (LEQEMBI)Alzheimer's DiseaseMarketed
Lenvatinib (LENVIMA)Renal Cell CarcinomaRegulatory Review
TaletrectinibROS1-Positive Non-Small Cell Lung CancerRegulatory Review
Lenvatinib + PembrolizumabVarious Solid TumorsPhase 3 / Marketed
Mycetoma Investigational DrugMycetomaClinical Development

Leadership Team at Eisai

KN
Keisuke Naito
Representative Director, President and COO
KY
Koichi Yanagawa
Representative Director, Chairman and CEO
IC
Ivan Cheung
Former Chairman and CEO of Eisai Inc. (U.S.)
View full Eisai profile